Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

Published:2013-06-10 Issue:6 Volume:14 Page:537-545
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Pierce Aisling,McGowan Patricia M.,Cotter Maura,Mullooly Maeve,O’Donovan Norma,Rani Sweta,O’Driscoll Lorraine,Crown John,Duffy Michael J.

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.24349

Reference29 articles.

1. The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets

2. PARP inhibition: PARP1 and beyond

3. Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

5. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study;The Breast;2024-10

2. CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines;Scientific Reports;2023-10-31

3. Updates in the Pathology and Therapy of BRCA Germline–Associated Breast Cancer with a Focus on HER2 Amplification;Current Breast Cancer Reports;2023-08-11

4. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo;Gynecologic Oncology;2023-03

5. Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance;Biomedicines;2021-10-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3